Skip to main content

Advertisement

Log in

Cyclin D1 (CCND1) G870A polymorphisms and cervical cancer susceptibility: a Meta-analysis based on Ten case–control studies

  • Research Article
  • Published:
Tumor Biology

Abstract

Many studies have evaluated the association between cyclin D1 (CCND1) G870A polymorphism and cervical cancer susceptibility. However, these studies showed inconsistent results. The aim of this study was to derive a more precise estimation of this association. We searched PubMed and Embase for related studies that had been published in English, and ten case–control studies with a total of 2,864 cases and 3,898 controls were finally identified to be eligible studies in the meta-analysis. The association was assessed by summarizing the odds ratios (ORs) with the corresponding 95 % confidence intervals (CIs). Overall, there was no significant association between cyclin D1 (CCND1) G870A polymorphism and cervical cancer risk (for the allele model A vs. G: OR = 1.02, 95 % CI 0.88–1.19, p = 0.76; for the co-dominant model AA vs. GG: OR = 1.03, 95 % CI 0.75–1.41, p = 0.85; for the dominant model AA + GA vs. GG: OR = 1.00, 95 % CI 0.78–1.28, p = 0.99; for the recessive comparison AA vs. GA + GG: OR = 1.06, 95 % CI 0.85–1.32, p = 0.62). In subgroup analysis by ethnicity, no significant difference was found in both Asians and Caucasians. In summary, the present meta-analysis provides evidence that genotypes for the cyclin D1 (CCND1) G870A polymorphism may be not associated with genetic susceptibility of cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461–84. doi:10.1016/s0140-6736(11)61351-2.

    Article  PubMed  Google Scholar 

  2. On the rise globally, cancer mortality declines in u.s. Cancer discovery. 2014;4(3):Of7. doi:10.1158/2159-8290.cd-nb2014-006.

  3. Amirian ES, Adler-Storthz K, Scheurer ME. Associations between human herpesvirus-6, human papillomavirus and cervical cancer. Cancer Lett. 2013;336(1):18–23. doi:10.1016/j.canlet.2013.04.023.

    Article  CAS  PubMed  Google Scholar 

  4. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(10):687–97. doi:10.7326/0003-4819-155-10-201111150-00376. W214-5.

    Article  PubMed  Google Scholar 

  5. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108.

    Article  CAS  PubMed  Google Scholar 

  6. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11(5):1005–11.

    CAS  PubMed  Google Scholar 

  7. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63(21):7056–61.

    CAS  PubMed  Google Scholar 

  8. Wang N, Qian X, Wang S, Gao H, Wang L, Huo Y, et al. CCND1 rs9344 polymorphisms are associated with the genetic susceptibility to cervical cancer in Chinese population. Mol Carcinog. 2012;51(2):196–205. doi:10.1002/mc.20801.

    Article  CAS  PubMed  Google Scholar 

  9. Ni J, Wang M, Wang M, Fu S, Zhou D, Zhang Z, et al. CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis. J Cancer Res Clin Oncol. 2011;137(3):489–94. doi:10.1007/s00432-010-0904-x.

    Article  CAS  PubMed  Google Scholar 

  10. Catarino R, Pereira D, Breda E, Coelho A, Matos A, Lopes C, et al. Oncogenic virus-associated neoplasia: a role for cyclin D1 genotypes influencing the age of onset of disease? Biochem Biophys Res Commun. 2008;370(1):118–22. doi:10.1016/j.bbrc.2008.03.039.

    Article  CAS  PubMed  Google Scholar 

  11. Catarino R, Matos A, Pinto D, Pereira D, Craveiro R, Vasconcelos A, et al. Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet. 2005;160(1):49–54. doi:10.1016/j.cancergencyto.2004.11.017.

    Article  CAS  PubMed  Google Scholar 

  12. Thakur N, Hussain S, Kohaar I, Tabassum R, Nasare V, Tiwari P, et al. Genetic variant of CCND1: association with HPV-mediated cervical cancer in Indian population. Biomark: Biochem Indic Expo Response Susceptibility Chem. 2009;14(4):219–25. doi:10.1080/13547500902825274.

    Article  CAS  Google Scholar 

  13. Satinder K, Chander SR, Pushpinder K, Indu G, Veena J. Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population. Mol Cell Biochem. 2008;315(1–2):151–7. doi:10.1007/s11010-008-9799-0.

    Article  CAS  PubMed  Google Scholar 

  14. Castro FA, Haimila K, Sareneva I, Schmitt M, Lorenzo J, Kunkel N, et al. Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population–a candidate gene approach. Int J Cancer J Int Du Cancer. 2009;125(8):1851–8. doi:10.1002/ijc.24529.

    Article  CAS  Google Scholar 

  15. Warchol T, Kruszyna L, Lianeri M, Roszak A, Jagodzinski PP. Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma. Pathol Oncol Res: POR. 2011;17(1):133–7. doi:10.1007/s12253-010-9293-3.

    Article  CAS  PubMed  Google Scholar 

  16. Djansugurova LB, Perfilyeva AV, Zhunusova GS, Djantaeva KB, Iksan OA, Khussainova EM. The determination of genetic markers of age-related cancer pathologies in populations from Kazakhstan. Front Genet. 2013;4:70. doi:10.3389/fgene.2013.00070.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Jeon YT, Kim JW, Song JH, Park NH, Song YS, Kang SB, et al. Cyclin D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix in Korean women. Cancer Lett. 2005;223(2):259–63. doi:10.1016/j.canlet.2004.12.024.

    Article  CAS  PubMed  Google Scholar 

  18. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4(11):850–60. doi:10.1038/nrc1476.

    Article  CAS  PubMed  Google Scholar 

  19. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10(8):772–84. doi:10.1016/s1470-2045(09)70187-1.

    Article  CAS  PubMed  Google Scholar 

  20. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer J Int Du Cancer. 2011;129(4):920–30. doi:10.1002/ijc.25710.

    Article  CAS  Google Scholar 

  21. Castro FA, Ivansson EL, Schmitt M, Juko-Pecirep I, Kjellberg L, Hildesheim A, et al. Contribution of TMC6 and TMC8 (EVER1 and EVER2) variants to cervical cancer susceptibility. Int J Cancer J Int Du Cancer. 2012;130(2):349–55. doi:10.1002/ijc.26016.

    Article  CAS  Google Scholar 

  22. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.

    Article  CAS  PubMed  Google Scholar 

  23. Zhou C, An H, Hu M, Liu Q, Geng P, Xu J, et al. The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: a meta-analysis. Tumour Biol: J Int Soc Oncodevelop Biol Med. 2013. doi:10.1007/s13277-013-0968-8.

    Google Scholar 

  24. Zhang LQ, Wang J, Shang JQ, Bai JL, Liu FY, Guan X, et al. Cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Int J Color Dis. 2011;26(10):1249–55. doi:10.1007/s00384-011-1220-x.

    Article  Google Scholar 

  25. Wang W, Zhao Y, Yang J, Lin B, Gu H, Cao X, et al. Cyclin D1 polymorphism and oral cancer: a meta-analysis. Mol Biol Rep. 2013;40(1):87–95. doi:10.1007/s11033-012-2025-x.

    Article  PubMed  Google Scholar 

  26. Tang C, Wang Z, Yu J, Wu Y, Zhu Z, Chen N. CCND1 G870A polymorphism and risk for head and neck cancer: a meta-analysis. Med Oncol (Northwood, London, England). 2011;28(4):1319–24. doi:10.1007/s12032-010-9547-7.

    Article  CAS  Google Scholar 

  27. Sergentanis TN, Economopoulos KP. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. Mol Biol Rep. 2011;38(8):4955–63. doi:10.1007/s11033-010-0639-4.

    Article  CAS  PubMed  Google Scholar 

  28. Li M, Dai W, Zhou H. Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a meta-analysis. Sci World J. 2013;2013:689048. doi:10.1155/2013/689048.

    Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Sciences Foundation of China (No. 81272334).

Conflicts of interest

None

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Huiling Yang or Dongyun Qin.

Additional information

Yongfu Wu and Hui Fu contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, Y., Fu, H., Zhang, H. et al. Cyclin D1 (CCND1) G870A polymorphisms and cervical cancer susceptibility: a Meta-analysis based on Ten case–control studies. Tumor Biol. 35, 6913–6918 (2014). https://doi.org/10.1007/s13277-014-1929-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1929-6

Keywords

Navigation